- Home
- HRMY vs NUV Comparison
HRMY vs NUV Comparison
Compare HRMY & NUV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- NUV
- Stock Information
- Founded
- HRMY 2017
- NUV 1987
- Country
- HRMY United States
- NUV United States
- Employees
- HRMY N/A
- NUV N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- NUV Trusts Except Educational Religious and Charitable
- Sector
- HRMY Health Care
- NUV Finance
- Exchange
- HRMY Nasdaq
- NUV Nasdaq
- Market Cap
- HRMY 1.6B
- NUV 1.8B
- IPO Year
- HRMY 2020
- NUV N/A
- Fundamental
- Price
- HRMY $34.05
- NUV $8.71
- Analyst Decision
- HRMY Strong Buy
- NUV
- Analyst Count
- HRMY 8
- NUV 0
- Target Price
- HRMY $52.88
- NUV N/A
- AVG Volume (30 Days)
- HRMY 701.6K
- NUV 464.9K
- Earning Date
- HRMY 05-06-2025
- NUV 01-01-0001
- Dividend Yield
- HRMY N/A
- NUV 3.96%
- EPS Growth
- HRMY 13.13
- NUV N/A
- EPS
- HRMY 2.62
- NUV N/A
- Revenue
- HRMY $744,852,000.00
- NUV N/A
- Revenue This Year
- HRMY $20.06
- NUV N/A
- Revenue Next Year
- HRMY $18.40
- NUV N/A
- P/E Ratio
- HRMY $13.10
- NUV N/A
- Revenue Growth
- HRMY 20.62
- NUV N/A
- 52 Week Low
- HRMY $26.47
- NUV $7.86
- 52 Week High
- HRMY $41.61
- NUV $9.08
- Technical
- Relative Strength Index (RSI)
- HRMY 69.53
- NUV 55.91
- Support Level
- HRMY $29.82
- NUV $8.60
- Resistance Level
- HRMY $30.61
- NUV $8.74
- Average True Range (ATR)
- HRMY 1.12
- NUV 0.07
- MACD
- HRMY 0.74
- NUV 0.02
- Stochastic Oscillator
- HRMY 92.78
- NUV 86.21
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About NUV Nuveen Municipal Value Fund Inc.
Nuveen Municipal Value Fund Inc is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax by investing in a portfolio of municipal obligations issued by state and local government authorities or certain U.S. territories.